Alex Bryant, MD, University of Michigan, Ann Arbor, MI, discusses why PSA is a good biomarker for prostate cancer but also explains its disadvantages, and discusses how polygenic risk scores could be used to identify patient sub-groups in which PSA could be a more specific biomarker than in the wider population. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
